ASX Announcement – 11 November 2026 MRI MUSCLE VOLUME & QUALITY ENDPOINT DEVELOPMENT UPDATE A MILESTONE IN MRI ENDPOINTS FOR OBESITY & METABOLIC TRIALS Highlights • Design and testing of Resonance Health’s MRI muscle volume and quality endpoint is complete – an important milestone in its...
MRI Muscle Endpoint - Product Update
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Resonance Health Ltd has announced the completion of the design and testing of its MRI muscle volume and quality endpoint, marking a significant milestone in its development strategy for MRI endpoints in clinical trials. This endpoint will allow clinical trial sponsors to measure various muscle quality metrics, including intramuscular fat and muscle volume, from a single MRI session. The company plans to offer this investigational endpoint to customers following the completion of necessary software verification and validation activities. The MRI Muscle Endpoint is specifically designed for use in obesity and metabolic trials, addressing the growing need for comprehensive muscle assessments in these studies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Resonance Health
- Alteration to Notice of Meeting
- Cleansing Notice
- Application for quotation of securities - RHT
- TrialsWest East-Coast Expansion - Executive Appointment
- Liver Fibrosis Device Webinar Presentation
Later from Resonance Health
All Resonance Health news releasesFollow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health